FIG. 5.

Effects of anti-CD122 antibodies on HSV-induced enhancement of NK activity. PBMC were mock treated or treated with HSV-1, washed and incubated in the presence of anti-CD122 or control antibodies for 24 h, and used as effectors in NK assays. The data show the average ± SE NK activities of these PBMC. A, mock-treated PBMC; B, HSV-treated PBMC; C, HSV-treated PBMC incubated in the presence of anti-CD122 antibodies; D, HSV-treated PBMC incubated in the presence of control antibodies; E, HSV-treated PBMC incubated in the presence of anti-IL-15 antibodies.